Abstract 80P
Background
The standard treatment for glioblastoma multiforme involves surgery followed by temozolomide (TMZ) treatment. However, many patients develop TMZ resistance either due to autophagic clearance of unwanted materials or reversal of TMZ-induced DNA alterations by methyl guanine o-methyl transferase. Additionally, other drugs are often ineffective because they cannot cross the blood-brain barrier (BBB). Hence, our objective is to repurpose FDA-approved drugs capable of crossing BBB and regulating autophagic pathways.
Methods
We identified differentially expressed genes regulating cellular processes in GBM, and used the Connectivity-MAP (C-Map) database to identify potential drugs, capable of reversing differentially expressed autophagy-associated genes. Following in-silico screening, we conducted cytotoxicity assays with selected drugs to evaluate IC50 values of drugs in 2-D and 3-D models. Additionally, immunoblotting and IF were performed to examine protein expression. Furthermore, we employed MDC staining to identify autophagic vacuoles, Annexin-PI to quantify apoptotic cells.
Results
Analysing GEO dataset, we identified top 10 dysregulated genes. Most downregulated genes were calcium signaling, while upregulated ones were PI3-Akt pathway. After identifying key genes and associated pathways, we used C-Map to identify top 5 drugs with high connectivity scores and BBB penetrance. They were assessed in vitro for their potential against GBM. Among them, Doxylamine and Gemfibrozil exhibited the best cytotoxicity, surpassing the standard drug TMZ. These drugs also hindered autophagic flux, verified by increased p62 and LC3B II proteins. Overexpression of PERK and CHOP confirmed ER stress-induced apoptosis. Furthermore, inhibition of Calmodulin, Calreticulin, and Calnexin post-drug-stress influenced the calcium signaling pathway. AnnexinV-PI assay demonstrated that increased ER stress and subsequent restriction of autophagic flux led to cell death.
Conclusions
Our research highlighted that doxylamine and gemfibrozil could serve as potential alternatives to TMZ for inducing apoptosis, by inhibiting autophagy, inducing ER stress, and generating ROS.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Indian Council of Medical Research (ICMR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
105P - Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Toxicity profile antibody-drug conjugates (ADCs) in metastatic breast cancer patients: A systematic review and meta-analysis based on studies’ design
Presenter: Silvia Belloni
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Receptor change on residual disease following neoadjuvant therapies for locally advanced breast cancer fails to impact oncological and survival outcomes
Presenter: Rionagh Lynch
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Presenter: Davide Ciardiello
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - Impact of tissue factor on clinical and biological characteristics in patients with advanced pancreatic cancer
Presenter: Taro Shibuki
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Multiomic profiling based on <italic>Akkermansia muciniphila</italic> in advanced non-small cell lung cancer
Presenter: Lorenzo Belluomini
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Transforming public patient omic data into precision oncology targets: A comprehensive pan-cancer approach
Presenter: Eléonore Fox
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Whole transcriptome sequencing of lung tissue to combine disease classification and identification of actionable targets
Presenter: Alejandro Pallares Robles
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - Genetic profiling of breast cancer in a developing country: Towards the establishment of oncogenetics in Cameroon
Presenter: Kenn Chi Ndi
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Uncovering the prognostic potential of FGFR2c isoform expression in advanced gastroesophageal cancer through MONSTAR-SCREEN-2 analysis
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract